高风险成人针对性乙型肝炎疫苗接种项目:最后一英里的根本挑战
本研究评估荷兰自2002年11月1日起由地区公共卫生服务机构运营的分散式针对性乙型肝炎疫苗接种项目对行为高风险群体的成本效果。基于截至2012年12月31日的数据,项目总体增量成本效果比为每获得一个QALY需30,400欧元,2002-2006年期间为24,200欧元/QALY,2007-2012年期间为42,400欧元/QALY;男男性行为者(MSM)的成本效果从20,700欧元/QALY降至47,700欧元/QALY。作者认为该项目对某些未接种的高风险成人是具有成本效果的干预,但风险群体内饱和、低风险行为个体参与及第二期招募投入增加使项目随时间推移成本效果降低。
要点
- 项目总体增量成本效果比为30,400欧元/QALY,效果与成本贴现率分别为1.5%和4%。
- 第一期(2002-2006年)成本效果为24,200欧元/QALY,优于第二期(2007-2012年)的42,400欧元/QALY。
- MSM的成本效果从20,700欧元/QALY降至47,700欧元/QALY。
核心结论
- 该分散式针对性乙型肝炎疫苗接种项目对某些未接种的高风险成人是具有成本效果的干预。
- 风险群体内饱和、低风险行为个体参与及第二期招募投入增加使项目随时间推移成本效果降低。
- 项目应讨论如何降低每个风险群体的成本、增加效果或何时将疫苗接种整合到常规医疗中。
研究设计与样本
- 基于截至2012年12月31日收集的参与者、疫苗接种和血清学数据,估算参与者数量和项目成本。
- 利用观察到的抗-HBc流行率估计各风险群体易感个体在余生中感染乙型肝炎病毒(HBV)的概率。
- 区分2002-2006年和2007-2012年两个时间段,代表不同招募策略和目标群体。
- 校正观察到的疫苗接种依从性后,估算各风险群体避免的未来HBV感染数。
- 结合Markov模型获得的寿命损失年、质量调整生命年损失和HBV感染医疗成本,分别估算各风险群体的项目效益。
主要发现
- 项目总体增量成本效果比为30,400欧元/QALY,效果和成本贴现率分别为1.5%和4%。
- 第一期成本效果为24,200欧元/QALY,第二期为42,400欧元/QALY。
- MSM的成本效果从20,700欧元/QALY降至47,700欧元/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate the cost-effectiveness of the on-going decentralised targeted hepatitis B vaccination program for behavioural high-risk groups operated by regional public health services in the Netherlands since 1-November-2002. Target groups for free vaccination are men having sex with men (MSM), commercial sex workers (CSW) and hard drug users (HDU). Heterosexuals with a high partner change rate (HRP) were included until 1-November-2007. METHODS: Based on participant, vaccination and serology data collected up to 31-December-2012, the number of participants and program costs were estimated. Observed anti-HBc prevalence was used to estimate the probability of susceptible individuals per risk-group to become infected with hepatitis B virus (HBV) in their remaining life. We distinguished two time-periods: 2002-2006 and 2007-2012, representing different recruitment strategies and target groups. Correcting for observed vaccination compliance, the number of future HBV-infections avoided was estimated per risk-group. By combining these numbers with estimates of life-years lost, quality-of-life losses and healthcare costs of HBV-infections - as obtained from a Markov model-, the benefit of the program was estimated for each risk-group separately. RESULTS: The overall incremental cost-effectiveness ratio of the program was €30,400/QALY gained, with effects and costs discounted at 1.5% and 4%, respectively. The program was more cost-effective in the first period (€24,200/QALY) than in the second period (€42,400/QALY). In particular, the cost-effectiveness for MSM decreased from €20,700/QALY to €47,700/QALY. DISCUSSION AND CONCLUSION: This decentralised targeted HBV-vaccination program is a cost-effective intervention in certain unvaccinated high-risk adults. Saturation within the risk-groups, participation of individuals with less risky behaviour, and increased recruitment investments in the second period made the program less cost-effective over time. The project should therefore discus how to reduce costs per risk-group, increase effects or when to integrate the vaccination in regular healthcare.
引用
- Mangen MJ, Stibbe H, Urbanus A, et al. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile. Vaccine. 2017. PMID: 28483198. doi:10.1016/j.vaccine.2017.04.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。